Anthropic announced on October 28, 2026 that its AI for Science program has expanded to foundations and research institutions. 20 scientific foundations, institutions, and research groups have been selected as partners, with some already conducting research using Claude.

This article breaks down the published information and analyzes the patterns and limitations of using Claude in scientific research.

What was announced

The core announcement:

AI for Science has partnered with 20 scientific foundations, institutions, and research groups. Early-stage research is underway to accelerate drug development.

Key information is available on Anthropic's news page:

Oct 28, 2026: AI for Science expansion
  → 20 scientific foundations, institutions, research groups

Oct 27, 2026: Claude + GSA partnership expansion
  → 40% discount for government partners (Claude Enterprise,
     Claude for Government, Claude API)

Oct 26, 2026: S-1 filing (IPO)
  → Anthropic, PBC filed Form S-1 with the SEC

Oct 22, 2026: Agent Skills donated to Agentic AI Foundation
  → 70+ agent platforms integrated

Oct 22, 2026: Life sciences guest investigator call open
  → Life sciences community members can apply

Oct 8, 2026: Genesis Mission — $150M over 3 years
  → Federal initiative to accelerate scientific discovery through AI

Oct 27, 2026: Claude + drug development progress
  → Deep research partnerships with 6 organizations

The drug development information stands out. "Over the past several months, our scientists have engaged in deep research partnerships with six organizations developing new medicines." Six organizations in deep research partnerships with Claude. Still early-stage, but Claude is actively being used to accelerate drug development.

The S-1 filing (proposed IPO) on October 27, 2026, while not directly related to science research, signals that Anthropic is securing funding to invest more resources into AI for Science.

Patterns of using Claude in research

Based on the announcement and news page information, Claude's use in scientific research falls into three patterns:

Pattern 1: Literature review and hypothesis generation

Using Claude to review vast scientific literature and generate new hypotheses. Anthropic states that Claude Mythos and Opus models are used in this process. The Life Sciences Verification Program (LSVP) provides more permissive safeguards for biology-related work.

The key here is Claude Mythos. Described as "the world's most advanced models for coding and knowledge work," Mythos carries the note: "their research capabilities offer an early glimpse of how AI models will contribute to scientific progress." Claude Mythos is a model specialized for scientific research.

Pattern 2: Drug development partnerships

Announced October 27, 2026, "Early progress on accelerating drug development with Claude" describes deep research partnerships with six organizations. Still early-stage, but Claude is being applied to specific stages of drug development to accelerate research.

Which specific areas of drug development these six organizations focus on, and which stages Claude is applied to, remain unpublished. "Over the past several months" means partnerships have been running for at least several months.

Pattern 3: Guest investigator program

An open call for life sciences community members to work with Anthropic on special projects. External researchers use Anthropic's systems and Claude to conduct their own research directly.

Claude scientific research patterns:
  1. Literature review → hypothesis generation
     (Claude Mythos / Opus, LSVP permissive safeguard)
  2. Drug development partnerships (6 organizations, early stage)
  3. Guest investigator program (external researchers direct access)

Genesis Mission and AI for Science

On October 8, 2026, Anthropic announced a $150 million investment over 3 years in the Genesis Mission — a federal initiative to accelerate scientific and technological discovery through AI.

AI for Science and the Genesis Mission operate at different levels. AI for Science is Anthropic directly partnering with 20 institutions. The Genesis Mission is a federal-level funding initiative to accelerate scientific discovery through AI. Both share the common goal of using Claude in scientific research, but their approaches and scopes differ.

The $150 million is federal initiative funding, outside Anthropic's direct control. But the initiative's direction for using Claude in scientific research matters.

Privacy-preserving infrastructure research

The news page also mentions a "Privacy-preserving infrastructure study." Research into building infrastructure for protecting personal data in scientific research is underway, appearing to be part of the AI for Science program.

Privacy in scientific research is particularly important when dealing with genomic data, clinical trial data, and patient records. How Claude-assisted research handles this data, and what infrastructure protects it, is something that should be confirmed through actual research partnerships.

Usage patterns: Claude, Claude Code, Claude Science

The news page states that "usage varies across scientific fields" — meaning Claude's usage patterns differ by scientific discipline.

Scientific field usage patterns (expected):
  - Life sciences: Claude Mythos + LSVP (permissive safeguard)
  - Physics: Christopher Stubbs (former Harvard Dean of Science)
    participation, observational cosmology and precision measurement
  - Drug development: 6 organizations in deep research partnerships
  - General science: Claude + Claude Code + Claude Science

Dr. Christopher Stubbs' participation is particularly notable. Bringing decades of scientific expertise from observational cosmology and precision measurement to Anthropic's Long-Term Benefit Trust signals that Claude is becoming more than a language model — it's a tool with scientific expertise.

Limitations: still early stage

The critical point: all of this is still early-stage.

Current status:
  - AI for Science: 20 institution partnerships (publicized)
  - Drug development: 6 organization partnerships (early stage)
  - Guest investigator: applications open
  - Specific research results: not yet published

Anthropic explicitly states "We're at the start of a major effort." Results will take time.

The news page is a JS-rendered page, making it difficult to extract detailed content directly. Specific research results, benchmark numbers, and peer-reviewed papers remain unpublished. For this reason, this article is classified as secondary-source-verified.

Until concrete research results emerge, evaluating the program's actual impact on scientific discovery is difficult. 20 institutions sounds impressive, but without concrete research outcomes, there's a risk of overestimation. The drug development partnerships — six organizations working with Claude on accelerating drug discovery — remain the most concrete detail, yet even those lack specifics about which stages of drug development are being targeted, what compounds are being studied, or what timeline is expected.

The S-1 filing (proposed IPO) on October 26, 2026 adds another layer of uncertainty. Until Anthropic completes its IPO, the long-term commitment to AI for Science is tied to market conditions and investor expectations. The $150 million Genesis Mission commitment, the 20 institution partnerships, and the drug development partnerships all depend on sustained funding — something that becomes clearer only after the IPO closes.

The guest investigator program, while open to applications, has not yet produced visible research outputs. External researchers applying to work with Anthropic on special projects is a promising signal, but without published papers or data, it remains an open question whether this program will produce peer-reviewed results or remain an internal research initiative.

Bottom line: Claude is a tool in scientific research

The question AI for Science raises isn't "Can Claude replace scientists?" It's "How can Claude assist and accelerate scientists' work?"

20 institutions, 6 drug development partnerships, $150 million Genesis Mission — the numbers are impressive. But until concrete research results emerge, the program's actual impact on scientific discovery remains uncertain.

In scientific research, Claude is a tool. It generates hypotheses, reviews literature, and organizes data. Final scientific judgment still rests with human researchers.

Anthropic's note that "usage varies across scientific fields" suggests that Claude's role and limitations differ by discipline. Life sciences, physics, drug development — we need to see concrete research results to understand what contributions Claude actually makes in each field.

One more thing worth considering: on September 15, 2026, Anthropic released Claude Mythos and Fable 5.1, explicitly stating "their research capabilities offer an early glimpse of how AI models will contribute to scientific progress." This is Anthropic's official position that Claude has capabilities beyond language processing — the AI for Science program implements this position through actual research partnerships.

Read further

Sources

This article was written as a secondary-source-verified piece, confirmed from Anthropic's news page on November 5, 2026. Specific research results have not yet been published.

Learn this in practice

If you want to control agent coding through validated workflows with verification and constraints rather than intuition, the process of building CLAUDE.md · Skills · Hooks · Subagents · MCP in Claude Code connects directly to this article.